157 related articles for article (PubMed ID: 37783645)
1. Exploring Barriers to Pediatric Cancer Clinical Trials: The Role of a Networked, Just-in-Time Study Program.
Rivers Z; Hyde B; Ronski K; Stearns D; Toll S; Ritt K; Cooney M; Nimeiri H; Federman N; Kaneva K
Clin Ther; 2023 Nov; 45(11):1148-1150. PubMed ID: 37783645
[TBL] [Abstract][Full Text] [Related]
2. The RACE for children act at one year: progress in pediatric development of molecularly targeted oncology drugs.
Zettler ME
Expert Rev Anticancer Ther; 2022 Mar; 22(3):317-321. PubMed ID: 35051348
[TBL] [Abstract][Full Text] [Related]
3. Navigating the Regulatory Landscape to Develop Pediatric Oncology Drugs: Expert Opinion Recommendations.
Barry E; Walsh JA; Weinrich SL; Beaupre D; Blasi E; Arenson DR; Jacobs IA
Paediatr Drugs; 2021 Jul; 23(4):381-394. PubMed ID: 34173206
[TBL] [Abstract][Full Text] [Related]
4. Clinical trial considerations for pediatric cancer drug development.
Cooner F; Ye J; Reaman G
J Biopharm Stat; 2023 Nov; 33(6):859-874. PubMed ID: 36749066
[TBL] [Abstract][Full Text] [Related]
5. Ushering in the next generation of precision trials for pediatric cancer.
DuBois SG; Corson LB; Stegmaier K; Janeway KA
Science; 2019 Mar; 363(6432):1175-1181. PubMed ID: 30872517
[TBL] [Abstract][Full Text] [Related]
6. Pediatric Cancer Drug Development: Leveraging Insights in Cancer Biology and the Evolving Regulatory Landscape to Address Challenges and Guide Further Progress.
Charlab R; Leong R; Shord SS; Reaman GH
Cold Spring Harb Perspect Med; 2024 Apr; 14(4):. PubMed ID: 38467448
[TBL] [Abstract][Full Text] [Related]
7. Pediatric Trials for Cancer Therapies With Targets Potentially Relevant to Pediatric Cancers.
Hwang TJ; Orenstein L; DuBois SG; Janeway KA; Bourgeois FT
J Natl Cancer Inst; 2020 Mar; 112(3):224-228. PubMed ID: 31665394
[TBL] [Abstract][Full Text] [Related]
8. New approaches to therapeutic drug development for childhood cancers.
Campbell K; Ma C; DuBois SG
Curr Opin Pediatr; 2020 Feb; 32(1):35-40. PubMed ID: 31790026
[TBL] [Abstract][Full Text] [Related]
9. Evolving paradigms for new agent development in pediatric oncology.
Flynn A; Fox E
Curr Opin Pediatr; 2018 Feb; 30(1):10-16. PubMed ID: 29176356
[TBL] [Abstract][Full Text] [Related]
10. Precision medicine in pediatric oncology.
Forrest SJ; Geoerger B; Janeway KA
Curr Opin Pediatr; 2018 Feb; 30(1):17-24. PubMed ID: 29189430
[TBL] [Abstract][Full Text] [Related]
11. Accelerating Pediatric Cancer Drug Development: Challenges and Opportunities for Pediatric Master Protocols.
Khan T; Stewart M; Blackman S; Rousseau R; Donoghue M; Cohen K; Seibel N; Fleury M; Benettaib B; Malik R; Vassal G; Reaman G
Ther Innov Regul Sci; 2019 Mar; 53(2):270-278. PubMed ID: 29759018
[TBL] [Abstract][Full Text] [Related]
12. Paediatric Strategy Forum for medicinal product development of epigenetic modifiers for children: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
Pearson AD; Stegmaier K; Bourdeaut F; Reaman G; Heenen D; Meyers ML; Armstrong SA; Brown P; De Carvalho D; Jabado N; Marshall L; Rivera M; Smith M; Adamson PC; Barone A; Baumann C; Blackman S; Buenger V; Donoghue M; Duncan AD; Fox E; Gadbaw B; Hattersley M; Ho P; Jacobs I; Kelly MJ; Kieran M; Lesa G; Ligas F; Ludwinski D; McDonough J; Nikolova Z; Norga K; Senderowicz A; Taube T; Weiner S; Karres D; Vassal G
Eur J Cancer; 2020 Nov; 139():135-148. PubMed ID: 32992153
[TBL] [Abstract][Full Text] [Related]
13. Opportunities and Challenges in Drug Development for Pediatric Cancers.
Laetsch TW; DuBois SG; Bender JG; Macy ME; Moreno L
Cancer Discov; 2021 Mar; 11(3):545-559. PubMed ID: 33277309
[TBL] [Abstract][Full Text] [Related]
14. Pediatric oncology enters an era of precision medicine.
Seibel NL; Janeway K; Allen CE; Chi SN; Cho YJ; Glade Bender JL; Kim A; Laetsch TW; Irwin MS; Takebe N; Tricoli JV; Parsons DW
Curr Probl Cancer; 2017; 41(3):194-200. PubMed ID: 28343740
[TBL] [Abstract][Full Text] [Related]
15. A Systematic Review of Pediatric Phase I Trials in Oncology: Toxicity and Outcomes in the Era of Targeted Therapies.
Cohen JW; Akshintala S; Kane E; Gnanapragasam H; Widemann BC; Steinberg SM; Shah NN
Oncologist; 2020 Jun; 25(6):532-540. PubMed ID: 31943534
[TBL] [Abstract][Full Text] [Related]
16. Advancing drug development in pediatric oncology, a focus on cancer biology and targeted therapies: iMATRIX platform.
Uguen M; Hilton M; Farid-Kapadia M; Datye A; Chohan S; Carlucci C; Dixon M; Elze M; Chen Y; Cheung KWK; Sane R; Zheng M; Choi Y
J Biopharm Stat; 2023 Nov; 33(6):800-811. PubMed ID: 36637189
[TBL] [Abstract][Full Text] [Related]
17. Access to innovative therapies in pediatric oncology: Report of the nationwide experience in Canada.
Judd S; Revon-Riviere G; Grover SA; Deyell RJ; Vanan MI; Lewis VA; Pecheux L; Zorzi AP; Goudie C; Santiago R; Tran TH; Abbott LS; Brossard J; Moorehead P; Alvi S; Portwine C; Denburg A; Whitlock JA; Cohen-Gogo S; Morgenstern DA
Cancer Med; 2024 Feb; 13(3):e7033. PubMed ID: 38400668
[TBL] [Abstract][Full Text] [Related]
18. Barriers and facilitators of clinical trial enrollment in a network of community-based pediatric oncology clinics.
Russo C; Stout L; House T; Santana VM
Pediatr Blood Cancer; 2020 Apr; 67(4):e28023. PubMed ID: 31556250
[TBL] [Abstract][Full Text] [Related]
19. Real-world performance analysis of a novel computational method in the precision oncology of pediatric tumors.
Vodicska B; Déri J; Tihanyi D; Várkondi E; Kispéter E; Dóczi R; Lakatos D; Dirner A; Vidermann M; Filotás P; Szalkai-Dénes R; Szegedi I; Bartyik K; Gábor KM; Simon R; Hauser P; Péter G; Kiss C; Garami M; Peták I
World J Pediatr; 2023 Oct; 19(10):992-1008. PubMed ID: 36914906
[TBL] [Abstract][Full Text] [Related]
20. Drug labeling changes and pediatric hematology/oncology prescribing: Measuring the impact of U.S. legislation.
Benning TJ; Shah ND; Inselman JW; Van Houten HK; Ross JS; Wyatt KD
Clin Trials; 2021 Dec; 18(6):732-740. PubMed ID: 34269090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
